

Executive Summary - Joint Working Project

Kent Surrey and Sussex (KSS) Diabetes Medical Technology Collaborative.

A collaborative approach to enhancing clinical outcomes and quality of life for adults with Type 1 diabetes by improving access and use of medical technology.

Summary of Joint Working Project:

This joint working project will enable a review of adult Type 1 diabetes services in specialist settings to reduce variation in access to NICE-compliant diabetes services that are high quality and cost effective.

Evidence suggests a minimum of 15-20 per cent of adult patients with Type 1 diabetes would meet the NICE criteria for insulin pump therapy, however The HSCIC National Diabetes Insulin Pump Audit Report, 2013-15, illustrates how there are significant challenges for Trust participation in data audits and considerable variation in access across England.

The number of adults currently using insulin pumps in KSS is largely unknown, but it is expected the number will be significantly lower than the recommended minimum of 15-20 per cent.

Participating Trusts will be supported through an improvement programme over 12 months, which will facilitate the service changes required to improve access and outcomes.

A series of 4 educational workshops will be run and each Trust team will also receive up to 4 one day sessions of on-site, facilitated improvement support.

The project will give Trusts an opportunity to explore how they will use technologies such as insulin pumps and continuous glucose monitoring (CGM), but may also extend to other technologies should Trusts choose to adopt innovative ways of working.

Data (access to technology and patient outcomes) will be collected and presented throughout the project and a full evaluation report will be completed 6 months after the improvement cycle.

The collaborative will comprise of an Industry Project Support Group which will provide advice, support and overall direction for the effective development and delivery of the project. IPSG will have shared responsibility for the successful delivery of the project and share an interest in, and contribute to, delivery of the project so that it results in outcomes that benefit patients.

The organisations involved in this Joint Working Project are:

- Kent Surrey Sussex Academic Health Science Network (KSS AHSN)
- South East Clinical Network
- Novo Nordisk
- Johnson & Johnson Diabetes Care Companies
- Dexcom

Job Bag Number: UK20PA00006

Date of Preparation: May 2020



Objectives of the Joint Working Project:

The joint working project will enable a review of adult Type 1 diabetes services in specialist settings to enhance clinical outcomes and quality of life for adults with Type 1 diabetes by improving access and use of medical technology.

Expected outcomes and patient benefits of the Joint Working Project

Expected benefits to patients:

Improved care quality and outcomes for Type 1 patient population
Reduced variation in access to insulin pumps for adults with Type 1 diabetes in accordance with NICE Guidance.
Reduced rate of mortality and improved quality of life for those with Type 1 diabetes.
Improved treatment outcomes and self-management of Type 1 diabetes.
Reduced diabetes complications associated with Type 1 diabetes through use of medical technology and better self-management.

Expected benefits to the NHS:

NICE-compliant diabetes services that are consistently accessible, high quality and cost effective.
Improved quality of data available for Type 1 diabetes to provide Trusts and CCGs with projections for future insulin pump uptake and requirements for planning services.
Reduced emergency hospital admissions and ambulance callouts due to Type 1 hypoglycaemia.
Reduced length of stay for inpatients with diabetes. Enhanced workforce capability access across the region.

Expected benefits to Novo Nordisk:

Benefits to Novo Nordisk would be through reduced variation, improved management and improved care pathways for patients with Type 1 diabetes.
Novo Nordisk Insulin and GLP products are widely included on local formularies. This includes Insulin Aspart, Insulin Detemir, Insulin Degludec, Biphasic Insulin Aspart, Human Insulin and Liraglutide.
An improvement in the uptake of pump therapy and the improved management of patients may result in an increase in the use of Novo Nordisk Insulin products.
Novo Nordisk will also gain a better understanding of how the NHS works in order to build our expertise for future collaborations and there will be wider benefits to the reputation of Novo Nordisk.

Each organisation within this Joint Working Project is contributing towards the following:

- Kent Surrey Sussex Academic Health Science Network will be leading the project, providing financial resources and a project team which includes data analytics and quality improvement expertise.



- South East Clinical Network will be supporting delivery of the project by providing financial resources and both strategic and clinical leadership.
- Novo Nordisk is providing support to commissioners, workshop facilitation, expertise in insulin management and a financial contribution to support the overall objectives of the collaborative project.
- Johnson and Johnson Diabetes Care Companies are providing education and training, access to products, support to commissioners, workshop facilitation and expertise in medical technology.
- Dexcom is providing education and training, access to products, support to commissioners, workshop facilitation, expertise in medical technology and a financial contribution to support the overall objectives of the collaborative project.

Joint Working Project measurements:

Baseline data will be collected at the start of the project to establish how many adults in Kent, Surrey and Sussex have access to medical technology as this data is largely unknown from the Health and Social Care Information Centre National Diabetes Insulin Pump Audit Report, 2013-15.

Data will be collected again after 6 and 12 months to demonstrate impact and allow publication of outcomes.

The data collected will identify the number of Trusts providing insulin pump services and the skill mix of the teams within the specialist services. The numbers of patients accessing pump therapy or CGM technology will also be identified, as will the arrangements for providing education to support self-management, for capturing patient satisfaction, and for the funding of medical devices. The baseline data is expected to highlight the variation in service provision for patients across the Kent, Surrey and Sussex region and the variation in quality of data recorded by the specialist teams and commissioners. Some of the improvements expected as a result of this project are a reduction in unwarranted variation of care quality for patients and improved access and use of technology which will help patients to better self-manage their diabetes, improve glycaemic control and reduce episodes of hypoglycaemia.

Timeframe of the Joint Working Project:

October 2017 – September 2018

October 2017 – Workshop 1

February 2018 – Workshop 2

June 2018 – Workshop 3

September 2018 – Workshop 4.

October 2018 – March 2019 – Project evaluation

March 2019 – publication of outcomes

Financial contribution:

Novo Nordisk is making a financial contribution to the project which will support:

The development of measurement tools and analyst time to implement and monitor progress to present performance back to teams.

The delivery of tailored on site educational support visits

The planning and delivery of educational workshops and associated costs, including venue hire and guest speakers.

The development of training and educational materials for workshops and tailored visits.

The recruitment of patient / carer participants which will enable learning from service users.

The facilitation of IPSP meetings.

Communications, marketing and photography for the workshops.